[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529384":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":35,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Chun-Hong Shen","2nd Affiliated Hospital, School of Medicine, Zhejiang University, China","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Mei-Ping Ding","CONTACT","+86 0571 87783872","dmp-neurology@zju.edu.cn",[20],{"facility":11,"status":21,"city":22,"state":23,"zip":7,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Hangzhou","Zhejiang","China","CN",{"type":27,"coordinates":28},"Point",[29,30],120.16142,30.29365,{"lat":30,"lon":29},[33],{"name":10,"role":16,"phone":17,"phoneExt":7,"email":34},"shen_neurology@zju.edu.cn",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Shen Chun-Hong","Associate Senior Doctor","100529384","a-prospective-study-to-evaluate-clinical-outcomes-in-anti-lgi1-encephalitis-100529384",false,"NCT06173076","A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis","A Prospective Study to Evaluate Clinical Outcomes in Patients With Anti-leucine-rich Glioma-inactivated 1 Encephalitis","Inclusion Criteria:\n\n1. Meet the 2016 consensus diagnostic criteria for anti-LGI1 encephalitis.\n2. Newly diagnosed, and during the acute stage before study enrollment.\n3. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. with the diagnosis of epilepsy, stroke, cerebral trauma, and\u002For other nervous system disease prior to the onset of encephalitis.\n2. with coexisting antibodies, such as anti-contactin-associated protein 2 (CASPR2) antibody.\n3. Lost to follow-up.","ALL","18 Years","100 Years",{"count":50,"type":51},60,"ESTIMATED","OBSERVATIONAL","Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. It presents with acute or subacute onset of epileptic seizures, anterograde amnesia, behavior disturbances, sleep disorders and hyponatremia. In most patients with anti-LGI1 encephalitis, immunotherapy is successful in treating the encephalitis. However, relapses, chronic epilepsy, cognitive declines and psychiatric problems have been reported in some cases.\n\nSo far, prospective studies to evaluate its clinical outcomes still remain limited. In this project, the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis.",[55,56],"Autoimmune Encephalitis","Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis","2025-08-20",{"date":59,"type":60},"2025-08-27","ACTUAL",{"date":62,"type":60},"2022-05-18",{"date":64,"type":51},"2032-12-31",{"name":37,"class":6},1]